Want to see ATYR full AI Analyst Report?

aTyr Pharma (ATYR) Price & Analysis

2,833 Followers

ATYR Stock Chart & Stats

$0.47

-$0.02(-4.98%)

At close: Jul 24 4:00 PM EDT

$0.47

-$0.02(-4.98%)

Day’s Range― - ―

52-Week Range$0.40 - $6.50

Previous CloseN/A

Volume825.96K

Average Volume (3M)1.96M

Market Cap

$49.19M

Enterprise Value$12.22

Total Cash (Recent Filing)$57.42M

Total Debt (Recent Filing)$11.30M

Price to Earnings (P/E)―

Beta1.16

Next Earnings

Nov 05, 2026

EPS Estimate

-0.1

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.62

Shares Outstanding98,087,425

10 Day Avg. Volume1,483,218

30 Day Avg. Volume1,963,911

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)1.08

Price to Sales (P/S)383.25

P/FCF Ratio-1.17

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$3.00

Price Target Upside538.30% Upside

Rating ConsensusHold

Number of Analyst Covering5

EPS Forecast (FY)-0.46

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthModest leverage and contained total debt reduce refinancing and interest-rate vulnerability versus peers. A stronger balance-sheet footing gives the company more optionality to fund a Phase 3 or secure partnerships without immediate heavy reliance on dilutive financings, supporting near-term program continuity.

Global Rights To Lead AssetRegaining exclusive global rights consolidates control of efzofitimod’s regulatory, clinical, and commercial strategy. Owning the asset worldwide simplifies development decisions, eliminates counterparty coordination costs, and preserves upside from future partnerships or commercialization deals long-term.

FDA-Aligned Phase 3 PlanConstructive FDA feedback and a redesigned global Phase 3 focused on validated endpoints materially lower regulatory and design risk. Alignment on objective functional and symptom measures should improve trial readthrough and long-term approval prospects in pulmonary sarcoidosis, a large underserved market.

Bears Say

Persistent Cash BurnSustained negative operating and free cash flow erodes cash reserves and forces recurring capital raises. Long-term cash burn increases dilution risk, limits strategic flexibility to run pivotal trials independently, and heightens dependency on external funding or partnerships to progress development programs.

Weak Revenue & ProfitabilityMinimal, volatile revenue and persistent large losses reflect a pre-commercial biotech profile with no durable operating cash generation. Continued negative profitability means the company cannot self-fund growth or pivot commercially, making long-term program advancement contingent on sustained financing.

Nasdaq Listing RiskAn ongoing minimum-bid noncompliance and reliance on extensions create material structural risk. Potential delisting would reduce liquidity, raise the cost of capital, impair investor access, and complicate future financing or partnership negotiations, constraining long-term strategic options.

aTyr Pharma News

aTyr Pharma reports Q2 EPS (11c), consensus (13c)

Cash, cash equivalents, restricted cash and available-for-sale investments as of June 30, 2026, were $58.9 million. Based on...

17d ago

ATYR

aTyr Pharma announces restructuring, will lay off roughly 60% of workforce

aTyr Pharma (ATYR) announced second quarter 2026 results and a corporate restructuring to prioritize its efzofitimod program in...

17d ago

ATYR

aTyr Pharma Regains Global Rights to Efzofitimod

aTyr Pharma ( ($ATYR) ) has shared an announcement. On May 12, 2026, aTyr Pharma received notice from...

24d ago

ATYR

aTyr Pharma Lawsuit: Company Asks Court to Dismiss Investor Securities Claims

aTyr Pharma (ATYR) and two executives have asked a federal court to dismiss an amended investor lawsuit over statements...

27d ago

ATYR

Joseph Pantginis Reiterates Hold as Efzofitimod Shifts to Restrictive Lung Phenotype After Mixed Phase 3 EFZO-FIT Results

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on ATYR stock, giving a Hold rating today....

1M ago

ATYR

aTyr Pharma Granted Nasdaq Extension to Regain Compliance

aTyr Pharma ( ($ATYR) ) has provided an announcement. On December 4, 2025, aTyr Pharma, Inc. disclosed that...

3M ago

ATYR

Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis

Atyr Pharma Inc. ($ATYR) announced an update on their ongoing clinical study. The Phase 3 study “A Phase...

3M ago

ATYR

aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data

aTyr Pharma ( ($ATYR) ) has issued an announcement. aTyr Pharma has updated investors on its strategy to...

3M ago

ATYR

aTyr Pharma upgraded to Buy from Hold at Freedom Broker

Freedom Broker upgraded aTyr Pharma (ATYR) to Buy from Hold with a price target of $3.50, up from...

3M ago

ATYR

aTyr Pharma Inc options imply 30.5% move in share price post-earnings

Pre-earnings options volume in aTyr Pharma (ATYR) Inc is normal with calls leading puts 142:1. Implied volatility suggests...

3M ago

ATYR

Midday Fly By: Applied Materials, Figma post ‘beat and raise’ reports

The major averages were broadly lower near noon, giving back some of yesterday’s gains as tech stocks lag,...

3M ago

DLO

aTyr Pharma reports Q1 EPS (11c), consensus (15c)

“2026 is off to a productive start, as we now have a clear path forward for efzofitimod in...

3M ago

ATYR

Boris Peaker Reiterates Hold as Constructive FDA Pathway Is Offset by Long Timelines and Funding Overhang for Efzofitimod Sarcoidosis Program

JonesTrading analyst Boris Peaker has maintained their neutral stance on ATYR stock, giving a Hold rating today. Boris...

3M ago

ATYR

Joseph Pantginis Reiterates Hold Rating as FDA Feedback Refocuses Phase 3 Trial Despite Prior Endpoint Miss

H.C. Wainwright analyst Joseph Pantginis has maintained their neutral stance on ATYR stock, giving a Hold rating yesterday....

3M ago

ATYR

ATYR FAQ

What was Atyr Pharma Inc.’s price range in the past 12 months?

Atyr Pharma Inc. lowest stock price was $0.40 and its highest was $6.50 in the past 12 months.

What is Atyr Pharma Inc.’s market cap?

Atyr Pharma Inc.’s market cap is $49.19M.

When is Atyr Pharma Inc.’s upcoming earnings report date?

Atyr Pharma Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 72 days.

How were Atyr Pharma Inc.’s earnings last quarter?

Atyr Pharma Inc. released its earnings results on Aug 07, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.121 by $0.011.

Is Atyr Pharma Inc. overvalued?

According to Wall Street analysts Atyr Pharma Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Atyr Pharma Inc. pay dividends?

Atyr Pharma Inc. does not currently pay dividends.

What is Atyr Pharma Inc.’s EPS estimate?

Atyr Pharma Inc.’s EPS estimate is -0.1.

How many shares outstanding does Atyr Pharma Inc. have?

Atyr Pharma Inc. has 98,087,425 shares outstanding.

What happened to Atyr Pharma Inc.’s price movement after its last earnings report?

Atyr Pharma Inc. reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.121. Following the earnings report the stock price went up 3.327%.

Which hedge fund is a major shareholder of Atyr Pharma Inc.?

Currently, no hedge funds are holding shares in ATYR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

aTyr Pharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-31.23%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Atyr Pharma Inc.

aTyr Pharma, Inc. (ATYR) is a clinical-stage biotechnology company focused on discovering and developing therapeutics based on immunological pathways associated with tRNA synthetases, aiming to address immune-mediated and inflammatory diseases. The company’s lead program is efzofitimod (ATYR1923), an engineered protein therapeutic being evaluated primarily in interstitial lung disease and related pulmonary inflammatory conditions.

aTyr Pharma (ATYR) Earnings & Revenues

Historic Earnings Reports

ATYR Stock 12 Month Forecast

Average Price Target

$3.00

▲(538.30% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","-1":"-$1","1.25":"$1.25","3.5":"$3.5","5.75":"$5.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$7.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,1.25,3.5,5.75,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.485,0.9861538461538462,1.4873076923076924,1.9884615384615385,2.4896153846153846,2.9907692307692306,3.491923076923077,3.993076923076923,4.49423076923077,4.995384615384616,5.496538461538462,5.997692307692308,6.498846153846155,{"y":7,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.485,0.6784615384615384,0.8719230769230769,1.0653846153846154,1.2588461538461537,1.4523076923076923,1.6457692307692309,1.839230769230769,2.0326923076923076,2.226153846153846,2.4196153846153847,2.613076923076923,2.8065384615384614,{"y":3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.485,0.5246153846153846,0.5642307692307692,0.6038461538461538,0.6434615384615384,0.683076923076923,0.7226923076923077,0.7623076923076924,0.801923076923077,0.8415384615384616,0.8811538461538462,0.9207692307692308,0.9603846153846154,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.65,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.69,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.866,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.741,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.783,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.97,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.99,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.85,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.833,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.546,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.589,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.485,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >